Lanean...
Comparing cost of intravenous infusion and subcutaneous biologics in COVID‐19 pandemic care pathways for rheumatoid arthritis and inflammatory bowel disease: A brief UK stakeholder survey
OBJECTIVES: One important group of people at higher risk from the SARS‐CoV‐2(COVID‐19) pandemic are those with autoimmune conditions including rheumatoid arthritis/inflammatory bowel disease. To minimise infection risk, many people have been switched from intravenous to subcutaneous biologics includ...
Gorde:
| Argitaratua izan da: | Int J Clin Pract |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
John Wiley and Sons Inc.
2021
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8236906/ https://ncbi.nlm.nih.gov/pubmed/33963659 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ijcp.14341 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|